KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
Metastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Activating alterations of KIT—a transmembrane receptor tyrosine kinase important for cell development, growth, and differentiation—have been shown to be critical to oncogenesis across many tumor subtypes. Following the successes of BRAF-targeted therapy in melanoma and KIT-targeted therapy in gastrointestinal stromal tumors, small-molecule tyrosine kinase inhibitors targeting KIT have been examined in KIT-mutated melanoma. KIT inhibitors that have been investigated in relevant clinical trials in advanced melanoma include imatinib, sunitinib, dasatinib, and nilotinib. In these studies, selected patients with KIT-mutated melanoma were shown to be responsive to therapy with KIT inhibition, especially patients with L576P and K642E mutations. This has led to the incorporation of KIT-targeted therapy in the National Comprehensive Cancer Network guidelines for systemic therapy for metastatic or unresectable melanoma. Current research and development efforts include novel KIT-targeted therapies and testing KIT inhibitors in combination with immunotherapy.
The results published or shown here are in part based upon data generated by The Cancer Genome Atlas (TCGA) research network: http://cancergenome.nih.gov/.
Compliance with Ethical Standards
Da Meng was funded by the Columbia University Vagelos College of Physicians and Surgeons 2018 Summer Research Program for the preparation of this manuscript.
Conflict of interest
Richard D. Carvajal is a consultant for AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Foundation Medicine, Immunocore, Incyte Merck, Novartis, Roche/Genentech, Aura Biosciences, Chimeron, and Rgenix. Da Meng has no conflicts of interest that might be relevant to the contents of this manuscript.
- 29.Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47(10):1194–9. https://doi.org/10.1038/ng.3382.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res. 2010;23(2):210–5. https://doi.org/10.1111/j.1755-148X.2010.00671.x.CrossRefPubMedGoogle Scholar
- 39.Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009;15(18):5902–9. https://doi.org/10.1158/1078-0432.CCR-09-0482.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116(5):772–82. https://doi.org/10.1182/blood-2009-12-256800.CrossRefPubMedGoogle Scholar
- 52.Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514–22. https://doi.org/10.1158/0008-5472.CAN-08-4709.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Christiansson L, Soderlund S, Mangsbo S, Hjorth-Hansen H, Hoglund M, Markevarn B, et al. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015;14(5):1181–91. https://doi.org/10.1158/1535-7163.MCT-14-0849.CrossRefPubMedGoogle Scholar
- 58.D’Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23(12):2972–80. https://doi.org/10.1158/1078-0432.CCR-16-2349.CrossRefPubMedGoogle Scholar
- 61.Evans E, Gardino A, Hodous B, Davis A, Zhu J, Kohl NE, et al. Blu-285, a potent and selective inhibitor for hematologic malignancies with KIT Exon 17 mutations. Blood. 2015;126:568.Google Scholar
- 62.Janku F, Razak A, Gordon M, Flynn D, Kaufman M, Pitman J, et al. Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST). Ann Oncol. 2017;28(5):14730.Google Scholar